XML 31 R19.htm IDEA: XBRL DOCUMENT v3.6.0.2
STOCKHOLDERS' EQUITY AND NONCONTROLLING INTERESTS
 3 Months Ended
Dec. 30, 2016
Equity [Abstract]  
STOCKHOLDERS’ EQUITY AND NONCONTROLLING INTERESTS
STOCKHOLDERS’ EQUITY AND NONCONTROLLING INTERESTS
Share Repurchase Program
In November 2016, the VMS Board of Directors authorized the repurchase of an additional 8.0 million shares of VMS common stock commencing on January 1, 2017. Share repurchases under the Company's authorizations may be made in open market purchases, in privately negotiated transactions (including accelerated share repurchase (“ASR”) programs), or under Rule 10b5-1 share repurchase plans, and may be made from time to time in one or more blocks. All shares that were repurchased under the Company's share repurchase programs have been retired. In November 2015, the VMS Board of Directors authorized the repurchase of 8.0 million shares of VMS common stock through December 31, 2016. As of December 30, 2016 the remaining 3.3 million shares under this authorization have expired.
The Company repurchased shares of VMS common stock under various authorizations during the periods presented as follows:
 
Three Months Ended
(In millions, except per share amounts)
December 30,
2016
 
January 1,
2016
Number of shares
0.5

 
2.4

Average repurchase price per share
$
98.98

 
$
79.20

Total cost
$
49.5

 
$
192.1



Other Comprehensive Earnings
The changes in accumulated other comprehensive loss by component and related tax effects are summarized as follows:
(In millions)
Net Unrealized Gains
(Losses) Defined
Benefit Pension and
Post-Retirement
Benefit Plans
 
Cumulative
Translation
Adjustment
 
Accumulated
Other
Comprehensive
Loss
Balance at September 30, 2016
$
(63.3
)
 
$
(37.5
)
 
$
(100.8
)
Other comprehensive loss before reclassifications
—

 
(13.1
)
 
(13.1
)
Amounts reclassified out of other comprehensive earnings
0.9

 
—

 
0.9

Tax expense
(0.1
)
 
—

 
(0.1
)
Balance at December 30, 2016
$
(62.5
)
 
$
(50.6
)
 
$
(113.1
)

 (In millions)
Net Unrealized Gains
(Losses) Defined
Benefit Pension and
Post-Retirement
Benefit Plans
 
Net
Unrealized
Gains
(Losses)
Cash Flow
Hedging
Instruments
 
Net
Unrealized
Gains
(Losses)
Available-for-
Sale
Securities
 
Cumulative
Translation
Adjustment
 
Accumulated
Other
Comprehensive Earnings
(Loss)
Balance at October 2, 2015
$
(46.1
)
 
$
—

 
$
(0.1
)
 
$
(40.3
)
 
$
(86.5
)
Other comprehensive earnings (loss) before reclassifications
—

 
0.1

 
(0.4
)
 
(4.6
)
 
(4.9
)
Amounts reclassified out of other comprehensive earnings
0.6

 
—

 
0.6

 
—

 
1.2

Tax expense
(0.1
)
 
—

 
(0.1
)
 
—

 
(0.2
)
Balance at January 1, 2016
$
(45.6
)
 
$
0.1

 
$
—

 
$
(44.9
)
 
$
(90.4
)

 
The amounts reclassified out of other comprehensive loss into the Condensed Consolidated Statements of Earnings, with line item location, during each period were as follows: 
 
Three Months Ended
 
 
 (In millions)
December 30,
2016
 
January 1,
2016
 
 
Comprehensive Earnings Components
Income (Loss) Before Taxes
 
Line Item in Statements of Earnings
Unrealized loss on defined benefit pension and post-retirement benefit plans
$
(0.9
)
 
$
(0.6
)
 
Cost of revenues & Operating expenses
Unrealized loss on available-for-sale-investments
—

 
(0.6
)
 
Operating expenses
Total amounts reclassified out of other comprehensive earnings
$
(0.9
)
 
$
(1.2
)
 
 
 
Noncontrolling Interests
In April 2015, the Company completed the acquisition of 73.5% of the then outstanding shares of MeVis Medical Solutions AG ("MeVis"), a public company based in Bremen, Germany that provides image processing software and services for cancer screening.
In August 2015, the Company, through one of its German subsidiaries, entered into a domination and profit and loss transfer agreement (the “DPLTA”) with MeVis. In October 2015, the DPLTA became effective upon its registration at the local court of Bremen, Germany. Under the DPLTA, MeVis subordinates its management to the Company and undertakes to transfer all of its annual profits and losses to the Company. In return, the DPLTA grants the noncontrolling shareholders of MeVis: (1) an annual recurring net compensation of €0.95 per MeVis share starting from January 1, 2015 and (2) a put right for their MeVis shares at €19.77 per MeVis share. Upon effectiveness of the DPLTA, the noncontrolling interests in MeVis became redeemable as a result of the put right and were reclassified to temporary equity. As of December 30, 2016, the redemption value of redeemable noncontrolling interests in MeVis was $10.3 million.
During the three months ended December 30, 2016, an immaterial number of MeVis' shares were purchased under the put right. As of December 30, 2016, noncontrolling shareholders together held approximately 0.5 million shares of MeVis, representing 26.3% of the outstanding shares.

Changes in noncontrolling interests and redeemable noncontrolling interests relating to MeVis and other subsidiaries of the Company were as follows:
 
Three Months Ended
 
Three Months Ended
 
December 30, 2016
 
January 1, 2016
 (In millions)
Noncontrolling Interests
 
Redeemable Noncontrolling Interests
 
Noncontrolling Interests
 
Redeemable Noncontrolling Interests
Balance at beginning of period
$
3.7

 
$
10.3

 
$
14.7

 
$
—

Net earnings attributable to noncontrolling interests
0.5

 
0.1

 
—

 
—

Reclassification of noncontrolling interests in MeVis to redeemable noncontrolling interests
—

 
—

 
(10.4
)
 
10.4

Other
—

 
(0.1
)
 
(0.5
)
 
—

Balance at end of period
$
4.2

 
$
10.3

 
$
3.8

 
$
10.4

In conjunction with the separation and distribution of Varex in January 2017, the Company's redeemable noncontrolling interests were transferred to Varex.